Red Light Holland Rebrands to Rhelion Life Sciences, Advances Naturally Derived Psilocybin Drug PEX010 Toward Phase II Clinical Development
核心洞察
Red Light Holland reported fiscal 2026 audited results and announced its corporate rebrand to Rhelion Life Sciences Corp. (搜索), effective August 4, 2026, reflecting a shift toward a science-first psychedelic drug development organization.
The acquisition of Filament Health Corp. provides Rhelion with 76 issued patents across 13 patent families, GMP manufacturing infrastructure, and the botanical psilocybin drug candidate PEX010, which has completed Phase I clinical development.
PEX010 and additional naturally derived psychedelic candidates are Phase II-ready, with the company actively exploring advancement into a Phase 2b clinical program targeting serious mental health and substance use disorders (搜索).
Red Light Holland Corp. (搜索) has reported its audited annual consolidated financial results for the fiscal year ended March 31, 2026, and provided a comprehensive update on its strategic transformation into a vertically integrated psychedelic drug discovery and development organization. The company also confirmed that its previously approved corporate rebrand to Rhelion Life Sciences Corp. (搜索) is expected to take effect on August 4, 2026, with shares continuing to trade under the tickers TRIP on the Canadian Securities Exchange, TRUFF on the OTCQB, and 4YX on the Frankfurt Stock Exchange.
The rebrand marks the culmination of a deliberate strategic pivot away from legacy operating businesses toward a science-first life sciences platform focused on naturally derived psychedelic medicines.
The Filament Health Acquisition: A Foundational Transformation
Central to the company's evolution is the acquisition of Filament Health Corp., which closed during fiscal 2026. The integration of Filament brings together proprietary intellectual property, GMP pharmaceutical-grade manufacturing capabilities, regulatory expertise, and an expanding international research network under one roof.
Key assets from the combined platform include 76 issued patents across 13 patent families, a Health Canada Level 8 Controlled Substances Dealer's Licence supporting the company's Vancouver-based laboratory and manufacturing facility, and GMP pharmaceutical-grade manufacturing infrastructure capable of producing botanical psilocybin capsules in doses ranging from 0.5 mg to 25 mg. The company's pharmaceutical-grade supply currently supports more than 80 clinical studies worldwide.
At the center of the pipeline is PEX010, a proprietary naturally derived botanical drug candidate that has successfully completed Phase I clinical development and is now Phase II-ready. The company is actively exploring opportunities to advance PEX010 into a Phase 2b clinical program, including evaluating CRO partners, trial design, regulatory pathways, and strategic financing alternatives.
Scientific Momentum and Clinical Development Plans
Throughout fiscal 2026, the company expanded its scientific and commercial reach through new research collaborations, pharmaceutical-grade supply agreements, and international partnerships. These initiatives include continued support for more than 80 clinical studies utilizing Filament's botanical drug candidates and preparations for additional Phase II clinical development initiatives focused on serious mental health and substance use disorders (搜索).
Todd Shapiro, Chief Executive Officer and Director, characterized the year as one of foundational building. "Fiscal 2026 was not about maximizing short-term revenue, it was about building the foundation and truly taking us from underground to mainstream," Shapiro stated. "The acquisition of Filament Health fundamentally changes who we are. Today, the Company combines one of the industry's largest portfolios of naturally derived psychedelic intellectual property with GMP pharmaceutical grade manufacturing, regulatory expertise, completed Phase I clinical development, Phase II-ready programs and a rapidly expanding international scientific network."
Shapiro further emphasized the mission going forward: "As we officially launch Rhelion Life Sciences, our mission is clear: responsibly advance naturally derived psychedelic medicines through rigorous science, disciplined execution and strategic partnerships while creating sustainable long-term value for patients, partners and shareholders."
Fiscal 2026 Financial Performance
The company reported total cash of $8.471 million for fiscal 2026, compared to $12.838 million in fiscal 2025, representing a decrease of $4.367 million. Revenue declined 15.15% to $4.195 million from $4.944 million in the prior year, while gross profit fell 16.84% to $1.591 million from $1.913 million.
General and administrative expenses decreased modestly by 4.56% to $5.426 million from $5.686 million. The adjusted EBITDA loss widened to $2.931 million from $2.532 million in fiscal 2025. Total assets stood at $14.570 million as of March 31, 2026, down from $21.221 million a year earlier.
The company noted that it held certain excess cash in Bitcoin exchange-traded funds and high-interest savings vehicles as part of its treasury investment strategy.
Divestiture of Non-Core Assets
As part of its strategic simplification, the company has been actively divesting non-core operating businesses. In June 2026, RLH Netherlands completed the sale of SR Wholesale to an arm's-length purchaser for cash consideration of €150,000, while retaining certain rights and assets associated with the iMicrodose brand and Wisdom Truffle inventory.
The company is evaluating strategic alternatives for MiniChamp, including a potential sale, and remains in discussions with a third party regarding the potential acquisition of its rights to farmland, plans, and permits at AEM Ontario in Peterborough. The land has been appraised at CAD$2 million, and the company has also engaged a realtor to potentially sell the land directly. Shiitake mushroom production at the AEM Farm in New Brunswick has been suspended since December 2025.
Fiscal 2027 Priorities and Outlook
Looking ahead to fiscal 2027, Rhelion Life Sciences intends to focus on advancing its naturally derived drug development platform. Key priorities include advancing PEX010 and additional naturally derived psychedelic drug candidates toward later-stage clinical development, expanding strategic licensing and pharmaceutical-grade supply opportunities, leveraging its intellectual property portfolio for commercialization, expanding GMP manufacturing capabilities, and evaluating additional strategic acquisitions and partnerships.
Management expressed confidence that the psychedelic medicine sector is entering a period of increasing regulatory acceptance and scientific validation. The company believes naturally derived botanical medicines will play an increasingly important role alongside synthetic compounds as regulators continue expanding clinical research pathways.
The company cautioned that its drug development programs remain subject to regulatory review and approval processes, and no assurance can be given that any product candidate will receive regulatory approval, advance to later-stage clinical development, or be successfully commercialized.